n(g),n(g')-dimethyl-l-arginine has been researched along with Dyslipidemia in 12 studies
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since co-administration of ezetimibe, a specific inhibitor of cholesterol absorption into the intestine, has been shown to augment lipid-lowering effects of statins, ezetimibe plus statins is a novel therapeutic strategy for the treatment of dyslipidemia in high-risk patients." | 9.14 | Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. ( Fujiwara, N; Fukami, K; Kawagoe, Y; Nakamura, T; Okuda, S; Sato, E; Suzuki, T; Ueda, S; Ueda, Y; Yamagishi, S, 2010) |
| "In rats with dyslipidemia, atorvastatin therapy could reduce plasma level of ADMA and ADMA concentration in cardiac tissues, and these effects are associated with the dose of atorvastatin therapy." | 7.81 | Atorvastatin protects endothelium by decreasing asymmetric dimethylarginine in dyslipidemia rats. ( Cai, A; Li, D; Liang, Q; Mai, W; Mai, Z; Qiu, R; Xu, R; Zeng, F; Zheng, D, 2015) |
| "The effects of eicosapentaenoic acid (EPA) on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure (CHF) patients with dyslipidemia remain unclear." | 7.80 | Effects of eicosapentaenoic acid on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure patients with dyslipidemia. ( Atarashi, H; Kohashi, K; Kosugi, M; Kusama, Y; Morisawa, T; Nakagomi, A; Saiki, Y; Shimizu, W, 2014) |
| "The aim of this study was to investigate serum leptin, oxidized low density lipoprotein (ox-LDL) and asymmetric dimethylarginine (ADMA) levels and their interaction with dyslipidaemia in adolescents with polycystic ovary syndrome (PCOS)." | 7.74 | Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. ( Biberoğlu, G; Bideci, A; Camurdan, MO; Cinaz, P; Demirel, F; Hasanoğlu, A; Yesilkaya, E, 2007) |
| "Dyslipidemia was defined as total cholesterol levels ≥200 mg/dL and/or triglyceride level ≥150 mg/dL." | 5.40 | Comparison of plasma viscosity as a marker of endothelial dysfunction with nitric oxide and asymmetric dimethylarginine in subjects with dyslipidemia. ( Ercan, M; Firtina, S; Konukoglu, D, 2014) |
| "Since co-administration of ezetimibe, a specific inhibitor of cholesterol absorption into the intestine, has been shown to augment lipid-lowering effects of statins, ezetimibe plus statins is a novel therapeutic strategy for the treatment of dyslipidemia in high-risk patients." | 5.14 | Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. ( Fujiwara, N; Fukami, K; Kawagoe, Y; Nakamura, T; Okuda, S; Sato, E; Suzuki, T; Ueda, S; Ueda, Y; Yamagishi, S, 2010) |
| "In rats with dyslipidemia, atorvastatin therapy could reduce plasma level of ADMA and ADMA concentration in cardiac tissues, and these effects are associated with the dose of atorvastatin therapy." | 3.81 | Atorvastatin protects endothelium by decreasing asymmetric dimethylarginine in dyslipidemia rats. ( Cai, A; Li, D; Liang, Q; Mai, W; Mai, Z; Qiu, R; Xu, R; Zeng, F; Zheng, D, 2015) |
| "The effects of eicosapentaenoic acid (EPA) on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure (CHF) patients with dyslipidemia remain unclear." | 3.80 | Effects of eicosapentaenoic acid on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure patients with dyslipidemia. ( Atarashi, H; Kohashi, K; Kosugi, M; Kusama, Y; Morisawa, T; Nakagomi, A; Saiki, Y; Shimizu, W, 2014) |
| "The aim of this study was to investigate serum leptin, oxidized low density lipoprotein (ox-LDL) and asymmetric dimethylarginine (ADMA) levels and their interaction with dyslipidaemia in adolescents with polycystic ovary syndrome (PCOS)." | 3.74 | Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. ( Biberoğlu, G; Bideci, A; Camurdan, MO; Cinaz, P; Demirel, F; Hasanoğlu, A; Yesilkaya, E, 2007) |
| " However, poor polyphenol bioavailability and extensive metabolization restrict their applicability." | 2.72 | Increasing the Power of Polyphenols through Nanoencapsulation for Adjuvant Therapy against Cardiovascular Diseases. ( Baião, DDS; da Silva, DVT; Paschoalin, VMF; Trindade, LR, 2021) |
| "Dyslipidemia was defined as total cholesterol levels ≥200 mg/dL and/or triglyceride level ≥150 mg/dL." | 1.40 | Comparison of plasma viscosity as a marker of endothelial dysfunction with nitric oxide and asymmetric dimethylarginine in subjects with dyslipidemia. ( Ercan, M; Firtina, S; Konukoglu, D, 2014) |
| "Ezetimibe treatment (10mg/day) for 6 months significantly decreased circulating levels of LDL-cholesterol, triglycerides and ADMA, while it increased HDL-cholesterol levels." | 1.35 | Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. ( Adachi, H; Fujiwara, N; Kawagoe, Y; Nakamura, T; Okuda, S; Sato, E; Suzuki, T; Ueda, S; Ueda, Y; Yamagishi, S, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Trindade, LR | 1 |
| da Silva, DVT | 1 |
| Baião, DDS | 1 |
| Paschoalin, VMF | 1 |
| Venkatesh, R | 1 |
| Srinivasan, K | 1 |
| Singh, SA | 1 |
| Wielkoszyński, T | 1 |
| Zalejska-Fiolka, J | 1 |
| Strzelczyk, JK | 1 |
| Owczarek, AJ | 1 |
| Cholewka, A | 1 |
| Furmański, M | 1 |
| Stanek, A | 1 |
| Ercan, M | 1 |
| Firtina, S | 1 |
| Konukoglu, D | 1 |
| Kohashi, K | 1 |
| Nakagomi, A | 1 |
| Saiki, Y | 1 |
| Morisawa, T | 1 |
| Kosugi, M | 1 |
| Kusama, Y | 1 |
| Atarashi, H | 1 |
| Shimizu, W | 1 |
| Zheng, D | 1 |
| Liang, Q | 1 |
| Zeng, F | 1 |
| Mai, Z | 1 |
| Cai, A | 1 |
| Qiu, R | 1 |
| Xu, R | 1 |
| Li, D | 1 |
| Mai, W | 1 |
| Nakamura, T | 3 |
| Sato, E | 3 |
| Fujiwara, N | 3 |
| Kawagoe, Y | 3 |
| Ueda, Y | 3 |
| Suzuki, T | 3 |
| Ueda, S | 3 |
| Adachi, H | 2 |
| Okuda, S | 3 |
| Yamagishi, S | 3 |
| Yamada, S | 1 |
| Takeuchi, M | 1 |
| Fukami, K | 2 |
| Matsui, T | 1 |
| Nishiyama, Y | 1 |
| Ueda, M | 1 |
| Katsura, K | 1 |
| Otsuka, T | 1 |
| Abe, A | 1 |
| Nagayama, H | 1 |
| Katayama, Y | 1 |
| Demirel, F | 1 |
| Bideci, A | 1 |
| Cinaz, P | 1 |
| Camurdan, MO | 1 |
| Biberoğlu, G | 1 |
| Yesilkaya, E | 1 |
| Hasanoğlu, A | 1 |
| Schiffrin, EL | 1 |
| Lipman, ML | 1 |
| Mann, JF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Influence of Preoperative Hemodialysis or Intraoperative Modified Ultrafiltration on Postoperative Outcome for Patients With Severe Renal Dysfunction Undergoing Open Heart Surgery: Randomized, Controlled, Multicenter Clinical Trial[NCT00720967] | Phase 3 | 450 participants (Anticipated) | Interventional | 2008-11-30 | Not yet recruiting | ||
| Effect of Beraprost Sodium on Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy (BESTinDN Study)[NCT01796418] | 102 participants (Anticipated) | Interventional | 2013-03-31 | Recruiting | |||
| A Multicenter, Randomized Trial to Compare Xience and Vision Coronary Stents in the Same Multivessel Patient With Chronic Kidney Disease[NCT00818792] | Phase 2 | 215 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for n(g),n(g')-dimethyl-l-arginine and Dyslipidemia
| Article | Year |
|---|---|
Increasing the Power of Polyphenols through Nanoencapsulation for Adjuvant Therapy against Cardiovascular Diseases.
Topics: Antioxidant Response Elements; Antioxidants; Arginine; Cardiotonic Agents; Diabetes Mellitus; Drug C | 2021 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
1 trial available for n(g),n(g')-dimethyl-l-arginine and Dyslipidemia
| Article | Year |
|---|---|
Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Anticholesteremic Agents; Arginine; Azetidines; Cholesterol; Cho | 2010 |
9 other studies available for n(g),n(g')-dimethyl-l-arginine and Dyslipidemia
| Article | Year |
|---|---|
Effect of arginine:lysine and glycine:methionine intake ratios on dyslipidemia and selected biomarkers implicated in cardiovascular disease: A study with hypercholesterolemic rats.
Topics: Administration, Oral; Amino Acids; Animals; Arginine; Biomarkers; Body Weight; Cardiovascular Diseas | 2017 |
Oxysterols Increase Inflammation, Lipid Marker Levels and Reflect Accelerated Endothelial Dysfunction in Experimental Animals.
Topics: Animals; Arginine; Aryldialkylphosphatase; C-Reactive Protein; Cholesterol; Dyslipidemias; Homocyste | 2018 |
Comparison of plasma viscosity as a marker of endothelial dysfunction with nitric oxide and asymmetric dimethylarginine in subjects with dyslipidemia.
Topics: Adult; Aged; Arginine; Atherosclerosis; Biomarkers; Blood Viscosity; Dyslipidemias; Endothelium, Vas | 2014 |
Effects of eicosapentaenoic acid on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure patients with dyslipidemia.
Topics: Aged; Arginine; Biomarkers; Chemokine CCL2; Chromatography, High Pressure Liquid; Chronic Disease; D | 2014 |
Atorvastatin protects endothelium by decreasing asymmetric dimethylarginine in dyslipidemia rats.
Topics: Animals; Arginine; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Creatine Kinase; Dysl | 2015 |
Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner.
Topics: Adult; Arginine; Azetidines; Cholesterol; Dyslipidemias; Ezetimibe; Female; Humans; Kidney Failure, | 2009 |
Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients.
Topics: Adult; Arginine; Cross-Sectional Studies; Dyslipidemias; Female; Glycation End Products, Advanced; H | 2009 |
Asymmetric dimethylarginine (ADMA) as a possible risk marker for ischemic stroke.
Topics: Age Factors; Aged; Arginine; Biomarkers; Blood Glucose; Brain Ischemia; Cholesterol, LDL; Dyslipidem | 2010 |
Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome.
Topics: Adolescent; Apolipoproteins B; Arginine; Biomarkers; Case-Control Studies; Cholesterol; Cholesterol, | 2007 |